Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Converting HR+ Breast Cancer Into An Individualized Vaccine

Clinical Trial Details

Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible for this randomized trial that will be concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of the trial testing focal hypo-fractionated RT alone or with immunotherapy combinations. 

Patients will be on the study for a total of 5 months. This includes 4 months on active study intervention with breast surgery at week 16, and a one month follow-up period after surgery.

Key Eligibility: 
  • Post-menopausal women age 18 or older
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1 
  • Biopsy proven diagnosis of ER+PR- HER2- breast cancer
  • Clinical stage II-III breast cancer
  • Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document 
  • Adequate bone marrow reserve and liver function 

Study contact by location

Upper East Side - Manhattan


Sharanya Chandrasekhar
(646) 962-2196

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group